WST · West Pharmaceutical Services Inc · Financials

$365.01 -5.75 (-1.55%) At close · Oct 1

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$26.07B

70.38M

Volume · Oct 1 670.87K Avg daily vol (3M) 641.5K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$3.07B +6.3%

FY2025

Net Income

$493.7M +0.2%

FY2025

Gross Margin

35.91% +1.4pp

FY2025

Operating Margin

19.03% -0.7pp

FY2025

Diluted EPS

$6.79 +1.5%

FY2025

Operating Cash Flow

$754.8M +15.5%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	+2.1%	+7.4%	+8.2%	$3.35B – $3.38B	$3.33B	$3.07B	$2.89B	$2.95B^G	$2.89B^G	$2.83B^G	$2.15B^G	$1.84B	$1.72B	$1.6B	$1.51B	$1.4B	$1.42B	$1.37B	$1.27B	$1.19B	$1.1B	$1.06B	$1.05B
Cost of Revenue	+4.0%	+7.4%	+7.6%	—	$2.1B	$1.97B	$1.89B	$1.82B	$1.75B	$1.66B	$1.38B	$1.23B	$1.17B	$1.09B	$1.01B	$944M	$973.6M	$933.7M	$878.7M	$853M	$786.6M	$752.1M	$748.5M
Gross Profit	-1.0%	+7.5%	+9.2%	—	$1.22B	$1.1B	$998.5M	$1.13B	$1.14B	$1.18B	$767.8M	$605.7M	$545.4M	$512.9M	$501.4M	$455.8M	$447.8M	$434.7M	$387.7M	$339.3M	$318.1M	$303.6M	$302.6M
Gross Margin	—	—	—	—	—	35.91%	34.51%	38.28%	39.36%	41.52%	35.76%	32.92%	31.76%	32.07%	33.23%	32.56%	31.5%	31.77%	30.61%	28.46%	28.8%	28.76%	28.79%
Research & Development	+8.3%	+9.6%	+8.1%	—	$74.4M	$74.3M	$69.1M	$68.4M	$58.5M	$52.8M	$46.9M	$38.9M	$40.3M	$39.1M	$36.8M	$34.1M	$37.3M	$37.9M	$33.2M	$29.1M	$23.9M	$19.9M	$18.7M
Selling, General & Administrative	+7.5%	+5.4%	+5.4%	—	$426.8M	$393.6M	$338.5M	$353.4M	$316.9M	$362.8M	$302M	$272.7M	$262.9M	$246M	$239.6M	$233M	$228.7M	$234.9M	$218.1M	$191.1M	$187.7M	$177.7M	$159.3M
Amortization of Intangibles	-8.9%	-8.6%	-2.2%	—	—	$2.8M	$3.6M	$3.6M	$3.7M	$5.4M	$4.4M	$3.4M	$2.7M	$2.4M	$2.6M	$3.5M	$4.9M	$3.9M	$3.9M	$4.3M	$4.1M	—	—
Depreciation & Amortization	+12.4%	+9.5%	+6.7%	—	$181.4M	$171.4M	$155.4M	$137.3M	$120.6M	$122.3M	$109.1M	$103.4M	$104.4M	$96.7M	$90.7M	$89.9M	$90M	$85.2M	$76.9M	$75.7M	$73.2M	$68.1M	—
Restructuring Charges	—	+37.9%	—	—	—	—	—	—	—	—	—	—	—	—	$26.4M	—	—	—	$2.1M	$5.3M	—	—	—
Operating Income	-7.3%	+7.5%	+16.4%	—	$680.4M	$584.9M	$569.9M	$676M	$734M	$752.3M	$406.9M	$296.6M	$240.3M	$225.8M	$195.2M	$128.6M	$182M	$162.4M	$135.1M	$109.6M	$90.7M	$97.5M	$124.1M
Operating Margin	—	—	—	—	—	19.03%	19.7%	22.92%	25.43%	26.57%	18.95%	16.12%	13.99%	14.12%	12.93%	9.19%	12.8%	11.87%	10.67%	9.19%	8.21%	9.24%	11.81%
EBITDA	-4.0%	+7.9%	+13.2%	—	$861.8M	$756.3M	$725.3M	$813.3M	$854.6M	$874.6M	$516M	$400M	$344.7M	$322.5M	$285.9M	$218.5M	$272M	$247.6M	$212M	$185.3M	$163.9M	$165.6M	—
Interest Expense	-60.1%	-42.8%	-28.4%	—	$4.5M	$500K	$3M	$9M	$7.9M	$8.2M	$8.2M	$8.5M	$8.4M	$7.8M	$8.1M	$14.1M	$16.5M	$17M	$16.7M	$18.2M	$16.8M	$15.2M	$16M
Other Non-Operating Income	—	—	—	—	-$1M	-$1M	-$1M	$22M	-$54.1M	-$3.4M	-$5.6M	-$4.8M	$400K	$3.1M	$1.6M	—	—	—	—	$4.2M	-$100K	-$200K	—
Equity in Earnings of Unconsolidated Entities	-11.4%	-3.7%	+9.5%	—	$15.5M	$14.4M	$14.7M	$17.7M	$20.7M	$20.1M	$17.4M	$8.9M	$7.6M	$9.2M	$8.2M	$5.8M	$5.3M	$5.4M	$4.8M	$6.3M	$4.4M	$3M	$800K
Investment Income (Loss)	—	—	—	—	—	—	—	-$4.3M	-$3.5M	-$4.3M	-$2.5M	$0	—	—	—	—	—	—	—	—	—	—	—
Pretax Income	-4.0%	+8.4%	+17.9%	—	$693.6M	$600.9M	$585.5M	$698M	$679.9M	$748.9M	$401.3M	$291.8M	$240.7M	$222.4M	$189.8M	$116.1M	$169M	$147.1M	$108.6M	$92.7M	$74.5M	$83.1M	$109.5M
Income Tax	+2.0%	+10.9%	+16.5%	—	$144.2M	$121.6M	$107.5M	$122.3M	$114.7M	$107.2M	$72.5M	$59M	$41.4M	$80.9M	$54.4M	$26.3M	$47.2M	$40.2M	$32.7M	$23.5M	$13.6M	$13.5M	$23.7M
Net Income	-5.5%	+7.4%	+17.8%	—	$564.9M	$493.7M	$492.7M	$593.4M	$585.9M	$661.8M	$346.2M	$241.7M	$206.9M	$150.7M	$143.6M	$95.6M	$127.1M	$112.3M	$80.7M	$75.5M	$65.3M	$72.6M	$86M
Net Margin	—	—	—	—	—	16.06%	17.03%	20.12%	20.3%	23.37%	16.13%	13.14%	12.05%	9.42%	9.52%	6.83%	8.94%	8.21%	6.37%	6.33%	5.91%	6.88%	8.18%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	$0	$0	$600K
Comprehensive Income	+4.7%	+10.9%	—	—	$513.2M	$646.3M	$378.4M	$632.6M	$562.5M	$612.8M	$385.2M	$246.3M	$170M	—	—	—	—	—	—	—	$53.7M	$97.8M	$7.5M
EPS (Basic) USD/shares	-4.6%	+7.9%	+17.8%	—	$7.87	$6.83	$6.75	$7.98	$7.87	$8.89	$4.68	$3.27	$2.80	$2.04	$1.96	$1.33	$1.79	$1.61	$1.19	$1.12	$1.96	$2.21	$2.65
EPS (Diluted) USD/shares	-4.2%	+8.2%	+18.0%	$8.85 – $9.05*	$7.81	$6.79	$6.69^G	$7.88^G	$7.73^G	$8.67^G	$4.57^G	$3.21	$2.74	$1.99	$1.91	$1.30	$1.75	$1.57	$1.15	$1.08	$1.89	$2.12	$2.50
Shares Outstanding (Basic Avg) shares	-0.9%	-0.4%	0.0%	—	—	72.3M	73M	74.3M	74.4M	74.4M	73.9M	74M	73.9M	73.9M	73.3M	72M	70.9M	69.6M	68.1M	67.3M	33.3M	32.8M	32.4M
Shares Outstanding (Diluted Avg) shares	-1.4%	-0.8%	-0.2%	—	—	72.7M	73.7M	75.3M	75.8M	76.3M	75.8M	75.4M	75.4M	75.8M	75M	73.8M	72.8M	71.4M	71.8M	74M	36.7M	36.3M	36.1M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2025: $1.89B in buybacks, $689.4M in dividends.

Debt Profile

Completed filing coverage through Jul 14, 2026

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Latest reported total

USD 202,900,000

As of Jun 30, 2026

Tracked instruments

Stable identities across filings

Annual baseline

—

Latest approved 10-K total

Reported total debt history

As of	Reported label	Amount	Source
2026-06-30	total debt balance	USD 202,900,000	10-Q filed 2026-07-23 Debt and credit facilities – The total debt balance of $202.9 million at June 30, 2026 is consistent with the total debt balance of $202.8 million at December 31, 2025.

Debt data is being processed. Please check back later.

1 filing has incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

7.77×

Peer median 2.40×

EV/EBIT

37.97×

Peer median 28.40×

P/E (TTM)

47.43×

Peer median 36.01×

Peer medians compare against the 20 similar-size Medical Instruments & Supplies companies (of 47 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Proprietary Products	$2,492,100,000	$2,334,500,000	$2,397,300,000	$2,406,800,000	$2,317,300,000	$1,648,600,000	$1,398,600,000	$1,308,600,000
Contract Manufactured Products	$582,000,000	$558,700,000	$552,500,000	$480,400,000	$514,700,000	$498,600,000	$441,500,000	$409,100,000

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$1,329,600,000	$1,230,800,000	$1,238,500,000	$1,286,500,000	$1,198,000,000	$975,600,000	$814,700,000	$766,100,000
Other Europe Countries	$451,000,000	$385,500,000	$388,100,000	$359,200,000	$341,300,000	$236,800,000	$251,100,000	$230,500,000
Germany	$380,300,000	$372,500,000	$406,100,000	$398,700,000	$474,300,000	$282,100,000	$236,300,000	$235,900,000
Other Countries	$353,300,000	$339,000,000	$348,500,000	$364,300,000	$357,400,000	$253,700,000	$213,400,000	$201,800,000
Ireland	$333,300,000	$323,200,000	$285,700,000	$240,300,000	$247,600,000	$226,000,000	$173,800,000	$138,100,000
France	$226,600,000	$242,200,000	$282,900,000	$237,900,000	$213,000,000	$172,700,000	$150,600,000	$145,000,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Proprietary Products	$657,200,000	$577,800,000	$710,100,000	$784,400,000	$796,100,000	$434,500,000	$313,600,000	$266,400,000
Contract Manufactured Products	$63,400,000	$72,300,000	$72,100,000	$60,400,000	$67,200,000	$68,600,000	$49,100,000	$44,300,000
Corporate and Eliminations	—	—	—	—	—	—	-$66,100,000	-$70,400,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Proprietary Products	26.4%	24.8%	29.6%	32.6%	34.4%	26.4%	22.4%	20.4%
Contract Manufactured Products	10.9%	12.9%	13%	12.6%	13.1%	13.8%	11.1%	10.8%

Key facts CIK 105770 CUSIP 955306105 13F (30d) 19 filings 15 filers Visit website Investor relations